1. In Vivo
  2. >>Deal-Making

Dealmaking Quarterly Statistics, Q1 2021

A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, January-March 2021

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma merger and acquisition value reached $34.8bn and drew in $35bn in potential deal value (PDV) from alliances. Device company M&A values reached $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.

Qstats Image 1
• Source: Alamy

Biopharma merger and acquisition value for the first quarter of 2021 totaled $34.8bn from 39 transactions, a significant drop in both deal value and volume versus Q4’s $73.9bn from 49 deals. Note that just over half of the Q4 total was from AstraZeneca’ s definitive agreement to acquire public rare disease drug developer Alexion Pharmaceuticals for $39bn (set to close in Q3 2021); if we remove this outlier, the Q4 total dollar value is $34.9bn, more in line with the Q1 2021 aggregate. The top three transactions of Q1 were not by big pharma, but instead a variety of biopharma players (see Exhibit 1).

The largest M&A of the quarter was a definitive agreement by ICON plc (global provider of outsourced drug and device...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Deal-Making

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

More from In Vivo

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Execs On The Move: June 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.